InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: None

Thursday, 11/03/2016 2:00:31 PM

Thursday, November 03, 2016 2:00:31 PM

Post# of 48316
If toxicity levels were to become an ongoing problem with Opdivo and also Keytruda, maybe Merck would be interested in a trial involving EP-IL12 +Keytruda in Responders as well as non-responders but at lower dosages of Keytruda.